Practical Considerations for Demonstrating Drug Substance Uniformity - The authors describe considerations and best practices for meeting drug substance uniformity. - BioPharm International

ADVERTISEMENT

Practical Considerations for Demonstrating Drug Substance Uniformity
The authors describe considerations and best practices for meeting drug substance uniformity.


BioPharm International
Volume 24, Issue 4, pp. 30-37

CONCLUSION

Drug-substance uniformity is an important consideration for the final step in the manufacture of API. Uniformity validation studies are necessary to ensure that the entire contents of the batch are homogenous and that the drug substance specification and stability samples are representative of the batch in terms of critical quality attributes. Using risk-based approaches and comprehensive process characterization studies, appropriate test parameters (e.g., protein concentration) and sample points (beginning, middle, and end) can be selected. Scientifically sound strategies which may be used in combination for developing uniformity acceptance criteria include those based on specification limits, measurement error, tolerance intervals of historical data and equivalency of sample means. Additionally, operational considerations, such as filter weight checks, pre-processing air drying, product flush, and the use of wet testing and/or engineering runs provide greater assurance of robust and consistent drug substance filtration and uniformity.

Sushil Abraham* is director of process development, Eric Rydholm, is principal engineer, and Phil Wagner is senior engineer, all at Amgen, Longmont CO,
.

PEER REVIEWED Article submitted: Oct. 20, 2010. Article accepted: Feb. 11, 2011.

REFERENCES

1. 21 CFR 211 (Government Printing Office, Washington DC), section 110.

2. G.B. Limenati, Analy. Chem. 6, 1A–6A, (2005).

3. S. Richter and A. Richter, Qual. Engin. 14 (3), 375–380 (2002).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here